La tuberculosis con resistencia a fármacos, sobre todo la que conlleva resistencia a rifampicina (TB-RR), se ha convertido en uno de los principales obstáculos para alcanzar el sueño de erradicar esta enfermedad. Y es que, para intentar curar la TB es necesario asociar tres o cuatro fármacos diferentes y, lamentablemente, son pocos los disponibles que se puedan considerar auténticamente eficaces. Pero, afortunadamente, el notable incremento que ha habido en los últimos años de la TB-RR en el mundo, ha motivado que se hayan invertido recursos en el desarrollo de nuevos fármacos para la TB, o que otros antimicrobianos investigados para otras enfermedades se hayan probado con éxito en la TB. Esto ha hecho que el manejo clínico de estos pacientes haya cambiado notablemente en los últimos tres a cuatro años, y resulte ahora más sencillo diseñar esquemas terapéuticos y conseguir mayores tasas de éxito. Todos estos cambios se actualizan en esta revisión. (AU)
Drug-resistant tuberculosis, especially those with resistance to rifampicin (RR-TB), has become one of the main obstacles to achieving the dream of eradicating tuberculosis. Furthermore, it is necessary to combine three or four different drugs in the attempt to cure TB, however, unfortunately, there are few available that can be considered genuinely effective. Fortunately, the notable worldwide increase in RR-TB in recent years has led to the investment of resources in the development of new drugs for TB, and other drugs investigated for other diseases have been successfully tested on TB. This has resulted in a clear change in the clinical management of these patients over the last 3-4 years, and it is now easier to design therapeutic regimens and achieve higher success rates. All these changes are updated in this review. (AU)
Humans , Antitubercular Agents/therapeutic use , Rifampin/therapeutic use , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/drug therapy , Communicable Diseases
Drug-resistant tuberculosis, especially those with resistance to rifampicin (RR-TB), has become one of the main obstacles to achieving the dream of eradicating tuberculosis. Furthermore, it is necessary to combine three or four different drugs in the attempt to cure TB, however, unfortunately, there are few available that can be considered genuinely effective. Fortunately, the notable worldwide increase in RR-TB in recent years has led to the investment of resources in the development of new drugs for TB, and other drugs investigated for other diseases have been successfully tested on TB. This has resulted in a clear change in the clinical management of these patients over the last 3-4 years, and it is now easier to design therapeutic regimens and achieve higher success rates. All these changes are updated in this review.
Extensively Drug-Resistant Tuberculosis , Mycobacterium tuberculosis , Tuberculosis, Multidrug-Resistant , Antitubercular Agents/therapeutic use , Extensively Drug-Resistant Tuberculosis/drug therapy , Humans , Rifampin/therapeutic use , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/epidemiology
No disponible
Humans , Male , Aged , Celiac Disease/diagnostic imaging , Celiac Disease/drug therapy , Tuberculosis/drug therapy , Antitubercular Agents/administration & dosage , Biopsy , Antitubercular Agents/classification , Antitubercular Agents/metabolism , Radiography, Thoracic , Bronchoscopy , Metronidazole/administration & dosage , Gastroscopy , Rifampin/administration & dosage
Antitubercular Agents/therapeutic use , Celiac Disease/complications , Isoniazid/adverse effects , Tuberculosis, Pulmonary/drug therapy , Aged , Antitubercular Agents/adverse effects , Celiac Disease/diet therapy , Diarrhea/chemically induced , Diarrhea/etiology , Diet, Gluten-Free , Drug Compounding , Drug Substitution , Drug Therapy, Combination , Ethambutol/therapeutic use , Glutens , Hemoptysis/etiology , Humans , Isoniazid/therapeutic use , Male , Metronidazole/therapeutic use , Moxifloxacin/therapeutic use , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Smoking/adverse effects , Tomography, X-Ray Computed , Tuberculosis, Pulmonary/complications
No disponible
Humans , Male , Middle Aged , Tuberculosis/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Positron Emission Tomography Computed Tomography , Tuberculosis, Pulmonary/drug therapy , Mycobacterium tuberculosis/isolation & purification , Radiography, Thoracic/methods , Sputum/microbiology , Sputum , Rifampin/therapeutic use , Pyrazinamide/therapeutic use , Isoniazid/therapeutic use , Ethambutol/therapeutic use , Mycobacterium tuberculosis
